Holen Sie sich die Stockscreener-App
53.81
0.28%
0.15
Handel nachbörslich:
53.74
-0.07
-0.13%
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Akero Therapeutics CEO Cheng sells $1.62m in shares - Investing.com
Advanced analytics toolkit walkthrough for Akero Therapeutics Inc.2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - Zenopa
Will Akero Therapeutics Inc. stock gain from lower inflationQuarterly Profit Review & AI Based Buy and Sell Signals - newser.com
Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com
Will Akero Therapeutics Inc. stock reach Wall Street targetsQuarterly Market Summary & Safe Capital Allocation Plans - newser.com
StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News
Novo Nordisk to Acquire Akero Therapeutics for $4.7B - Contract Pharma
Is Akero Therapeutics Inc. stock bottoming outWeekly Investment Report & Verified Stock Trade Ideas - newser.com
TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a 20% Upside Potential in Biotech - DirectorsTalk Interviews
Is Akero Therapeutics Inc. stock a buy before product launchesQuarterly Trade Summary & Fast Entry Momentum Trade Alerts - newser.com
Custom watchlist performance reports with Akero Therapeutics Inc.July 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues
Real time breakdown of Akero Therapeutics Inc. stock performanceMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post
The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter
Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Akero Therapeutics' (AKRO) Peer Perform Rating Reiterated at Wolfe Research - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Cut to "Neutral" at HC Wainwright - MarketBeat
Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) - GlobeNewswire Inc.
Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail
Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research
Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus
Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener
HC Wainwright Downgrades Akero Therapeutics to Neutral From Buy, $72 Price Target - MarketScreener
Novo makes bold $5.2bn bet on MASH treatment with Akero buy - BioXconomy
Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX (AKRO) - Seeking Alpha
Akero says new owner Novo Nordisk to drive commercialisation process - MarketScreener
Novo Nordisk analyst on Akero acquisition: Buys potentially best remedy for fatty liver - medwatch.com
Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout - ET Pharma
What drives Akero Therapeutics Inc 0K4 stock priceDividend Stability Analysis & Stocks With 200% Upside Potential - earlytimes.in
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsBull Run & Verified Stock Trade Ideas - newser.com
Akero Therapeutics Inc. stock momentum explainedJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN
Key facts: Novo Nordisk to Acquire Akero for $5.2 Billion; R&D Costs to Rise - TradingView
Novo Nordisk to Acquire Akero Therapeutics for $5.2B, Targeting Breakthrough Liver Drug - Azat TV
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Akero therapeutics CSO sells $576k in shares - Investing.com
Akero Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AKRO - Benzinga
Novo Nordisk to acquire clinical-stage drugmaker Akero Therapeutics - MLex
Novo Nordisk’s Akero Bid Centered On Addressing Cirrhotic MASH - insights.citeline.com
Novo buys Akero for $4.7B in third and largest deal in key liver disease class - BioCentury
Novo buying Akero for $4.7B to strengthen MASH portfolio - BioWorld MedTech
Why Akero Therapeutics Stock Trounced the Market on Thursday - The Globe and Mail
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):